摘要 |
Disclosed is a novel principle for dosing a specific anti-cancer drug compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt of said drug compound or prodrug thereof as described, wherein said drug compound, prodrug thereof or pharmaceutically acceptable salt of said drug compound or prodrug thereof is intravenously administered to a cancer patient according to a specific dosage frequency and a specific treatment cycle at a dose being below the maximum tolerated dose (MTD) defined for said dosage frequency and treatment cycle of said drug, prodrug thereof or pharmaceutically acceptable salt of said drug compound or prodrug thereof but providing at least the same exposure of the tissue of the cancer from which said cancer patient is suffering, to said drug as provided by the MTD at the same dosage frequency and treatment cycle. |